Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Diseases | 4 | 2021 | 9 | 1.030 |
Why?
|
| Fundus Oculi | 2 | 2021 | 2 | 0.800 |
Why?
|
| Gardner Syndrome | 1 | 2021 | 1 | 0.780 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2021 | 2 | 0.780 |
Why?
|
| Endophthalmitis | 4 | 2010 | 8 | 0.510 |
Why?
|
| Vitrectomy | 10 | 2010 | 15 | 0.450 |
Why?
|
| Tomography, Optical Coherence | 5 | 2021 | 16 | 0.300 |
Why?
|
| Drug Implants | 1 | 2006 | 12 | 0.280 |
Why?
|
| Ganciclovir | 1 | 2006 | 27 | 0.280 |
Why?
|
| Macula Lutea | 4 | 2016 | 7 | 0.280 |
Why?
|
| Foreign-Body Migration | 1 | 2006 | 20 | 0.280 |
Why?
|
| Visual Acuity | 11 | 2016 | 46 | 0.260 |
Why?
|
| Antiviral Agents | 1 | 2006 | 136 | 0.250 |
Why?
|
| Retinoschisis | 2 | 2014 | 2 | 0.230 |
Why?
|
| Retina | 4 | 2014 | 12 | 0.230 |
Why?
|
| Macular Edema | 2 | 2015 | 7 | 0.210 |
Why?
|
| Sutures | 2 | 2021 | 42 | 0.200 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2021 | 1 | 0.200 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 58 | 0.190 |
Why?
|
| Lenses, Intraocular | 1 | 2021 | 4 | 0.190 |
Why?
|
| Laser Coagulation | 2 | 2015 | 5 | 0.170 |
Why?
|
| Mutation | 1 | 2021 | 399 | 0.170 |
Why?
|
| Eye Proteins | 2 | 2016 | 8 | 0.160 |
Why?
|
| Fluorescein Angiography | 9 | 2016 | 12 | 0.160 |
Why?
|
| Retinal Perforations | 2 | 2010 | 2 | 0.150 |
Why?
|
| Humans | 24 | 2021 | 29851 | 0.150 |
Why?
|
| Glucocorticoids | 2 | 2015 | 69 | 0.140 |
Why?
|
| Fibrinolytic Agents | 2 | 2010 | 57 | 0.140 |
Why?
|
| Retinal Detachment | 4 | 2002 | 8 | 0.140 |
Why?
|
| Male | 18 | 2021 | 15871 | 0.140 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2016 | 1 | 0.140 |
Why?
|
| Choroid Diseases | 1 | 2016 | 3 | 0.140 |
Why?
|
| Retinal Degeneration | 1 | 2016 | 4 | 0.140 |
Why?
|
| Adult | 11 | 2021 | 8748 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2016 | 22 | 0.130 |
Why?
|
| Chloride Channels | 1 | 2016 | 10 | 0.130 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 6 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 18 | 0.130 |
Why?
|
| Macular Degeneration | 2 | 2005 | 3 | 0.130 |
Why?
|
| Dog Diseases | 1 | 1995 | 18 | 0.120 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 20 | 0.120 |
Why?
|
| Light Coagulation | 2 | 1995 | 2 | 0.120 |
Why?
|
| Myopia | 1 | 2013 | 2 | 0.110 |
Why?
|
| Middle Aged | 14 | 2014 | 9963 | 0.100 |
Why?
|
| Anesthesia, Intravenous | 1 | 1991 | 8 | 0.100 |
Why?
|
| Candidiasis | 1 | 1991 | 17 | 0.100 |
Why?
|
| Propofol | 1 | 1991 | 17 | 0.100 |
Why?
|
| Blindness | 2 | 2016 | 14 | 0.090 |
Why?
|
| Vitreous Detachment | 1 | 2010 | 1 | 0.090 |
Why?
|
| Acanthamoeba | 1 | 2010 | 2 | 0.090 |
Why?
|
| Acanthamoeba Keratitis | 1 | 2010 | 2 | 0.090 |
Why?
|
| Amebiasis | 1 | 2010 | 3 | 0.090 |
Why?
|
| Fibrinolysin | 1 | 2010 | 5 | 0.090 |
Why?
|
| Eye Infections, Parasitic | 1 | 2010 | 4 | 0.090 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2010 | 6 | 0.090 |
Why?
|
| Choroid | 2 | 1989 | 3 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2010 | 97 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 1989 | 57 | 0.090 |
Why?
|
| Female | 15 | 2014 | 16430 | 0.080 |
Why?
|
| Scleral Buckling | 4 | 1998 | 4 | 0.080 |
Why?
|
| Iatrogenic Disease | 1 | 1989 | 26 | 0.080 |
Why?
|
| Niacin | 1 | 2008 | 2 | 0.080 |
Why?
|
| Cataract Extraction | 1 | 2008 | 4 | 0.080 |
Why?
|
| Hypolipidemic Agents | 1 | 2008 | 22 | 0.080 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 1859 | 0.070 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2006 | 4 | 0.070 |
Why?
|
| Aged | 11 | 2014 | 9621 | 0.070 |
Why?
|
| Device Removal | 1 | 2006 | 86 | 0.070 |
Why?
|
| Choroidal Neovascularization | 1 | 2005 | 2 | 0.070 |
Why?
|
| Visual Field Tests | 1 | 2005 | 3 | 0.070 |
Why?
|
| Postoperative Complications | 7 | 2004 | 957 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 166 | 0.060 |
Why?
|
| Retinal Hemorrhage | 1 | 2004 | 3 | 0.060 |
Why?
|
| Retinitis Pigmentosa | 1 | 2004 | 2 | 0.060 |
Why?
|
| Semiconductors | 1 | 2004 | 4 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2004 | 42 | 0.060 |
Why?
|
| Electrodes, Implanted | 1 | 2004 | 47 | 0.060 |
Why?
|
| Prosthesis Implantation | 1 | 2004 | 35 | 0.060 |
Why?
|
| Laser Therapy | 2 | 1997 | 13 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2014 | 4930 | 0.050 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2002 | 2 | 0.050 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2002 | 6 | 0.050 |
Why?
|
| Lens, Crystalline | 1 | 2002 | 32 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2015 | 3561 | 0.050 |
Why?
|
| Chiropractic | 1 | 1980 | 2 | 0.050 |
Why?
|
| Vitreous Body | 2 | 2010 | 7 | 0.050 |
Why?
|
| Suture Techniques | 1 | 2021 | 141 | 0.040 |
Why?
|
| Retinal Vessels | 2 | 2016 | 3 | 0.040 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 1998 | 2 | 0.040 |
Why?
|
| Propranolol | 1 | 1998 | 13 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 1998 | 41 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1998 | 42 | 0.040 |
Why?
|
| Injections | 2 | 2010 | 59 | 0.040 |
Why?
|
| Hospital Charges | 1 | 1997 | 20 | 0.040 |
Why?
|
| Retrospective Studies | 4 | 2014 | 3325 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 245 | 0.030 |
Why?
|
| Anxiety | 1 | 1998 | 157 | 0.030 |
Why?
|
| Tremor | 1 | 1998 | 143 | 0.030 |
Why?
|
| Bestrophins | 1 | 2016 | 1 | 0.030 |
Why?
|
| RNA Splice Sites | 1 | 2016 | 3 | 0.030 |
Why?
|
| Iris | 1 | 2016 | 3 | 0.030 |
Why?
|
| Exons | 1 | 2016 | 38 | 0.030 |
Why?
|
| Ischemia | 1 | 2016 | 27 | 0.030 |
Why?
|
| Atrophy | 1 | 2016 | 106 | 0.030 |
Why?
|
| Lipids | 1 | 2015 | 36 | 0.030 |
Why?
|
| Lens Implantation, Intraocular | 2 | 2008 | 5 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2015 | 69 | 0.030 |
Why?
|
| Fluorocarbons | 1 | 1995 | 16 | 0.030 |
Why?
|
| Cryosurgery | 1 | 1995 | 20 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2015 | 112 | 0.030 |
Why?
|
| Microsurgery | 1 | 1995 | 40 | 0.030 |
Why?
|
| Dogs | 1 | 1995 | 261 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2015 | 252 | 0.030 |
Why?
|
| Internship and Residency | 1 | 1998 | 213 | 0.030 |
Why?
|
| Patient Selection | 1 | 2015 | 234 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 1997 | 401 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2010 | 522 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2013 | 10 | 0.030 |
Why?
|
| Recurrence | 2 | 1997 | 355 | 0.030 |
Why?
|
| Intraoperative Complications | 2 | 2004 | 71 | 0.030 |
Why?
|
| Adolescent | 5 | 2002 | 2334 | 0.030 |
Why?
|
| Suction | 1 | 1992 | 41 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1991 | 36 | 0.020 |
Why?
|
| Contact Lenses, Hydrophilic | 1 | 2010 | 2 | 0.020 |
Why?
|
| Eye Enucleation | 1 | 2010 | 2 | 0.020 |
Why?
|
| Antiprotozoal Agents | 1 | 2010 | 12 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 95 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 116 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2010 | 135 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 2467 | 0.020 |
Why?
|
| Pseudophakia | 1 | 2008 | 1 | 0.020 |
Why?
|
| Prednisolone | 1 | 2008 | 7 | 0.020 |
Why?
|
| Choroiditis | 1 | 1988 | 2 | 0.020 |
Why?
|
| Sclera | 2 | 1998 | 2 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2004 | 379 | 0.020 |
Why?
|
| Child | 3 | 1998 | 1379 | 0.020 |
Why?
|
| Animals | 1 | 1995 | 4639 | 0.020 |
Why?
|
| Photography | 1 | 2005 | 17 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2005 | 34 | 0.020 |
Why?
|
| Evoked Potentials, Visual | 1 | 2004 | 4 | 0.010 |
Why?
|
| Electroretinography | 1 | 2004 | 2 | 0.010 |
Why?
|
| Silicon | 1 | 2004 | 4 | 0.010 |
Why?
|
| Visual Fields | 1 | 2004 | 5 | 0.010 |
Why?
|
| Prone Position | 1 | 2004 | 29 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 399 | 0.010 |
Why?
|
| Pressure | 1 | 2004 | 61 | 0.010 |
Why?
|
| Safety | 1 | 2004 | 48 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2004 | 84 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 532 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 558 | 0.010 |
Why?
|
| Visual Perception | 1 | 2004 | 50 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 1969 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 258 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 803 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2004 | 403 | 0.010 |
Why?
|
| Silicone Oils | 1 | 2002 | 2 | 0.010 |
Why?
|
| New Zealand | 1 | 1980 | 13 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 1824 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 80 | 0.010 |
Why?
|
| Placebos | 1 | 1998 | 82 | 0.010 |
Why?
|
| Hospitals, Community | 1 | 1997 | 14 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1997 | 40 | 0.010 |
Why?
|
| Cost Savings | 1 | 1997 | 35 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 143 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 1998 | 138 | 0.010 |
Why?
|
| United States | 1 | 1980 | 2346 | 0.010 |
Why?
|
| Pigment Epithelium of Eye | 1 | 1988 | 2 | 0.000 |
Why?
|
| Eye Foreign Bodies | 1 | 1987 | 1 | 0.000 |
Why?
|
| Methods | 1 | 1986 | 17 | 0.000 |
Why?
|
| Acyclovir | 1 | 1986 | 5 | 0.000 |
Why?
|
| Retinitis | 1 | 1986 | 3 | 0.000 |
Why?
|
| Necrosis | 1 | 1986 | 27 | 0.000 |
Why?
|
| Acute Disease | 1 | 1986 | 225 | 0.000 |
Why?
|